Developer docs
API playgroundTry for free, no card

Search company profiles

BioCentriq

Full company profile

uuid0000zop

Namestring
BioCentriq
Legal namestring
Made Scientific
Websiteurl
biocentriq.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

BioCentriq (operating as Made Scientific) is a cell therapy contract development and manufacturing organization (CDMO) headquartered in Newark, New Jersey with its main 60,000 ft² Development Center of Excellence in Princeton, NJ. The company supports therapeutic developers and pharmaceutical/biotech firms across the full cell therapy lifecycle — pre-clinical support, Phase I-III clinical trials, and commercial enablement — across multiple cell types including T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes. Service modules span process and analytical development, GMP and non-GMP cell banking and drug product manufacture, GMP aseptic fill and finish, quality control lot release and stability studies, regulatory consulting for IND/BLA submissions, and workforce development through the Made Scientific Foundry™ program.

The underlying technology stack combines GMP-compliant manufacturing infrastructure (five ISO 7/Grade B cleanrooms, BSL-2 compliance, in-house QC labs, cryo-storage and cold-chain management) with proprietary platform technologies including MadeFast™ with RapidCell™, a single-step CAR-T manufacturing platform designed to accelerate time-to-clinic, and a viral clearance platform for AAV gene therapy co-developed with Cytiva under NIIMBL funding. The Princeton expansion adds 12,000 ft² of GMP cleanroom space with high-throughput suites featuring AI-driven robotic automation, targeting approximately 5,000 additional manufacturing batches per year at full capacity.

BioCentriq generates revenue through project-based CDMO contracts under three engagement models: traditional and dedicated service for all clients, hybrid client-in-plant operations for mid-to-late stage programs, and custom build-outs for late-stage and commercial clients, with multi-year dedicated capacity contracts available to secure supply chains. Pricing is quote-based and not publicly disclosed. The company closed a $29.2 million Series A in January 2024 to fund facility expansion, advanced technology investment, and team growth, and is led by CEO Syed Husain alongside VP of Development David Smith.

Short descriptiontext

BioCentriq (dba Made Scientific) is a U.S. cell therapy CDMO offering GMP development and manufacturing services across T Cells, NK Cells, HSCs, MSCs, iPSCs, and TILs from pre-clinical through commercial scale, serving pharma and biotech developers from its Princeton, NJ facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNewark, United States
HQ citystring
Newark
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, contract development services, GMP biopharmaceutical production, CAR-T cell therapy, viral vector manufacturing
Industry4 codes
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Cell Therapy Contract Development & Manufacturing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Fee-for-service CDMO model providing cell therapy development and GMP manufacturing services to pharmaceutical and biotech companies. Revenue generated through project-based contracts for process development, GMP manufacturing, quality control testing, regulatory consulting, and workforce training.

madescientific.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Traditional & Dedicated Service - Turnkey solutions with platform processes or purpose-built technology transfer plus dedicated capacity models
ModelOtherBilling cadenceMulti-year contract
Notes

Project-based pricing; dedicated capacity model available to secure supply chain

madescientific.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1MadeFast™
Description

Single-step CAR-T manufacturing platform with RapidCell™ technology

madescientific.com
+2 more records
Core offering1 text field

BioCentriq (operating as Made Scientific) is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, GMP manufacturing, and release services for cell therapies including T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes. Services span pre-clinical support through Phase I-III clinical trials and commercial enablement, with flexible engagement models including traditional dedicated service, hybrid client-in-plant operations, and custom build-outs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Approximately 5,000 additional manufacturing batches per year at full capacity from expansion
Product overview1 text field

Made Scientific is a cell therapy CDMO (Contract Development and Manufacturing Organization) offering a unified platform of manufacturing solutions. The core offering includes Cell Therapy CDMO Services supporting T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes from pre-clinical through commercial stages. Supporting service modules include Process & Analytical Development, GMP and Non-GMP Manufacturing, GMP Aseptic Fill & Finish, Quality Control Testing & Stability Studies, Regulatory Consulting, and Workforce Development & Training via Made Scientific Foundry™. The company also provides Ready-Made Platforms for fast-track IND filings and MadeFast™ with RapidCell™ as a proprietary single-step CAR-T manufacturing platform. Partnership models include Traditional & Dedicated Service, Hybrid Client-In-Plant Operations, and Custom Build-outs & Partnerships.

Product and service1 record
1Cell Therapy CDMO Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-28
Description

BioCentriq and Cytiva collaborated on a NIIMBL-funded project to develop a viral clearance platform for AAV manufacturing. The partnership aimed to accelerate gene therapy development through improved viral safety testing and clearance methodologies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Samsung Biologics is expanding into cell and gene therapy CDMO services alongside its large-scale biologics manufacturing. As a broad incumbent with deep capital resources, it represents a competitive threat as the cell therapy outsourcing market matures.

2Vineti
TypeEmerging player
Description

Vineti provides cell therapy supply chain orchestration software and related services. While not a direct manufacturing peer, it is an emerging ecosystem participant addressing adjacent workflow needs of cell therapy developers served by BioCentriq.

TypeBroad incumbent
Description

Lonza is one of the largest global CDMOs with a dedicated cell and gene therapy business offering process development, GMP manufacturing, and viral vector production. It is a broad incumbent serving overlapping pharmaceutical and biotech clients with comparable services across cell therapy modalities.

TypeEmerging player
Description

Cellares offers automated, high-throughput cell therapy manufacturing through its Cell Shuttle platform. It is an emerging player pursuing the same automation-driven throughput advantage that BioCentriq targets with its AI-driven robotic automation expansion.

TypeBroad incumbent
Description

Thermo Fisher provides cell therapy manufacturing services through its pharma services business (including legacy Brammer Bio viral vector capabilities). As a broad incumbent with global infrastructure, it competes for large pharma cell therapy outsourcing contracts.

TypeDirect peer
Description

AGC Biologics is a mid-sized global CDMO offering cell and gene therapy process development and GMP manufacturing. It is comparable to BioCentriq in scale and service scope, competing for similar biotech and pharmaceutical clients across cell modalities.

TypeBroad incumbent
Description

WuXi Advanced Therapies provides cell and gene therapy development, viral vector manufacturing, and GMP services globally. Its scale and broad service portfolio position it as a major competing CDMO for cell therapy developers.

TypeDirect peer
Description

Miltenyi Biotec offers cell therapy manufacturing services alongside its core cell separation instruments and reagents. It is directly comparable in cell therapy modalities served and in serving biotech developers needing GMP capacity.

TypeBroad incumbent
Description

Charles River provides cell therapy CDMO services, manufacturing support, and related safety/QC testing. Its broad life sciences footprint and integrated services make it a key comparator in the cell therapy manufacturing space.

TypeBroad incumbent
Description

Catalent's Cell & Gene Therapy division provides process development, manufacturing, and fill-finish for cell therapies including CAR-T and viral vectors. As a broad incumbent with multi-site capacity, it competes for the same enterprise pharma and biotech clients as BioCentriq.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioCentriq

Cell Therapy Contract Development & Manufacturingbiocentriq.com

BioCentriq (dba Made Scientific) is a U.S. cell therapy CDMO offering GMP development and manufacturing services across T Cells, NK Cells, HSCs, MSCs, iPSCs, and TILs from pre-clinical through commercial scale, serving pharma and biotech developers from its Princeton, NJ facility.

What BioCentriq does

BioCentriq (operating as Made Scientific) is a cell therapy contract development and manufacturing organization (CDMO) headquartered in Newark, New Jersey with its main 60,000 ft² Development Center of Excellence in Princeton, NJ. The company supports therapeutic developers and pharmaceutical/biotech firms across the full cell therapy lifecycle — pre-clinical support, Phase I-III clinical trials, and commercial enablement — across multiple cell types including T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes. Service modules span process and analytical development, GMP and non-GMP cell banking and drug product manufacture, GMP aseptic fill and finish, quality control lot release and stability studies, regulatory consulting for IND/BLA submissions, and workforce development through the Made Scientific Foundry™ program.

The underlying technology stack combines GMP-compliant manufacturing infrastructure (five ISO 7/Grade B cleanrooms, BSL-2 compliance, in-house QC labs, cryo-storage and cold-chain management) with proprietary platform technologies including MadeFast™ with RapidCell™, a single-step CAR-T manufacturing platform designed to accelerate time-to-clinic, and a viral clearance platform for AAV gene therapy co-developed with Cytiva under NIIMBL funding. The Princeton expansion adds 12,000 ft² of GMP cleanroom space with high-throughput suites featuring AI-driven robotic automation, targeting approximately 5,000 additional manufacturing batches per year at full capacity.

BioCentriq generates revenue through project-based CDMO contracts under three engagement models: traditional and dedicated service for all clients, hybrid client-in-plant operations for mid-to-late stage programs, and custom build-outs for late-stage and commercial clients, with multi-year dedicated capacity contracts available to secure supply chains. Pricing is quote-based and not publicly disclosed. The company closed a $29.2 million Series A in January 2024 to fund facility expansion, advanced technology investment, and team growth, and is led by CEO Syed Husain alongside VP of Development David Smith.

BioCentriq firmographics

Firmographics
Name
BioCentriq
Legal name
Made Scientific
Website
https://biocentriq.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
BioCentriq (dba Made Scientific) is a U.S. cell therapy CDMO offering GMP development and manufacturing services across T Cells, NK Cells, HSCs, MSCs, iPSCs, and TILs from pre-clinical through commercial scale, serving pharma and biotech developers from its Princeton, NJ facility.
Ownership category
akta.pro rank

BioCentriq industry classification

Industry
Product category
Cell Therapy Contract Development & Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cell therapy manufacturing
  • Contract development services
  • GMP biopharmaceutical production
  • CAR-T cell therapy
  • Viral vector manufacturing

Where BioCentriq is headquartered

Location

Headquarters

HQ city
Newark
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BioCentriq business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: Fee-for-service CDMO model providing cell therapy development and GMP manufacturing services to pharmaceutical and biotech companies. Revenue generated through project-based contracts for process development, GMP manufacturing, quality control testing, regulatory consulting, and workforce training.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractTraditional & Dedicated Service - Turnkey solutions with platform processes or purpose-built technology transfer plus dedicated capacity models

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

BioCentriq product offering

Product offering

Core offering

BioCentriq (operating as Made Scientific) is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, GMP manufacturing, and release services for cell therapies including T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes. Services span pre-clinical support through Phase I-III clinical trials and commercial enablement, with flexible engagement models including traditional dedicated service, hybrid client-in-plant operations, and custom build-outs.

Product overview

Made Scientific is a cell therapy CDMO (Contract Development and Manufacturing Organization) offering a unified platform of manufacturing solutions. The core offering includes Cell Therapy CDMO Services supporting T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes from pre-clinical through commercial stages. Supporting service modules include Process & Analytical Development, GMP and Non-GMP Manufacturing, GMP Aseptic Fill & Finish, Quality Control Testing & Stability Studies, Regulatory Consulting, and Workforce Development & Training via Made Scientific Foundry™. The company also provides Ready-Made Platforms for fast-track IND filings and MadeFast™ with RapidCell™ as a proprietary single-step CAR-T manufacturing platform. Partnership models include Traditional & Dedicated Service, Hybrid Client-In-Plant Operations, and Custom Build-outs & Partnerships.

Differentiator

Problem solved

Functional benefit

Brands

  • MadeFast™: Single-step CAR-T manufacturing platform with RapidCell™ technology
  • Made Foundry™
  • RapidCell™

Products and services

  • Cell Therapy CDMO Services

Quantifiable outcome

  • Approximately 5,000 additional manufacturing batches per year at full capacity from expansion

Companies that use BioCentriq

Customer profile

Segments3 records

Ideal customer profiles2 records

BioCentriq technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BioCentriq partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CytivacoreStrategic or Co-development Partner · 28 June 2023BioCentriq and Cytiva collaborated on a NIIMBL-funded project to develop a viral clearance platform for AAV manufacturing. The partnership aimed to accelerate gene therapy development through improved viral safety testing and clearance methodologies.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

BioCentriq competitors and assessment

Company assessment

Broad incumbents

  • Samsung Biologics: Samsung Biologics is expanding into cell and gene therapy CDMO services alongside its large-scale biologics manufacturing. As a broad incumbent with deep capital resources, it represents a competitive threat as the cell therapy outsourcing market matures.
  • Lonza Cell & Gene Technologies: Lonza is one of the largest global CDMOs with a dedicated cell and gene therapy business offering process development, GMP manufacturing, and viral vector production. It is a broad incumbent serving overlapping pharmaceutical and biotech clients with comparable services across cell therapy modalities.
  • Thermo Fisher Scientific (Patheon / Brammer Bio): Thermo Fisher provides cell therapy manufacturing services through its pharma services business (including legacy Brammer Bio viral vector capabilities). As a broad incumbent with global infrastructure, it competes for large pharma cell therapy outsourcing contracts.
  • WuXi Advanced Therapies Unit: WuXi Advanced Therapies provides cell and gene therapy development, viral vector manufacturing, and GMP services globally. Its scale and broad service portfolio position it as a major competing CDMO for cell therapy developers.
  • Charles River Laboratories: Charles River provides cell therapy CDMO services, manufacturing support, and related safety/QC testing. Its broad life sciences footprint and integrated services make it a key comparator in the cell therapy manufacturing space.
  • Catalent (Cell & Gene Therapy): Catalent's Cell & Gene Therapy division provides process development, manufacturing, and fill-finish for cell therapies including CAR-T and viral vectors. As a broad incumbent with multi-site capacity, it competes for the same enterprise pharma and biotech clients as BioCentriq.

Emerging players

  • Vineti: Vineti provides cell therapy supply chain orchestration software and related services. While not a direct manufacturing peer, it is an emerging ecosystem participant addressing adjacent workflow needs of cell therapy developers served by BioCentriq.
  • Cellares: Cellares offers automated, high-throughput cell therapy manufacturing through its Cell Shuttle platform. It is an emerging player pursuing the same automation-driven throughput advantage that BioCentriq targets with its AI-driven robotic automation expansion.

Direct peers

  • AGC Biologics: AGC Biologics is a mid-sized global CDMO offering cell and gene therapy process development and GMP manufacturing. It is comparable to BioCentriq in scale and service scope, competing for similar biotech and pharmaceutical clients across cell modalities.
  • Miltenyi Biotec: Miltenyi Biotec offers cell therapy manufacturing services alongside its core cell separation instruments and reagents. It is directly comparable in cell therapy modalities served and in serving biotech developers needing GMP capacity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

BioCentriq social profiles

Digital presence

BioCentriq financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioCentriq leadership team

Management profile

Number of profiles

Profiles2 records

BioCentriq funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioCentriq M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCentriq

What does BioCentriq do?

BioCentriq (operating as Made Scientific) is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, GMP manufacturing, and release services for cell therapies including T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes. Services span pre-clinical support through Phase I-III clinical trials and commercial enablement, with flexible engagement models including traditional dedicated service, hybrid client-in-plant operations, and custom build-outs.

Is BioCentriq a public or private company?

BioCentriq is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioCentriq founded?

BioCentriq was founded in 2019. It employs 101 to 250 people.

Where is BioCentriq based?

BioCentriq is headquartered in Newark, United States, in the North America region.

How does BioCentriq make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are BioCentriq's main competitors?

Broad incumbents on record are Samsung Biologics, Lonza Cell & Gene Technologies, Thermo Fisher Scientific (Patheon / Brammer Bio), WuXi Advanced Therapies Unit, Charles River Laboratories and Catalent (Cell & Gene Therapy). Emerging players are Vineti and Cellares. Direct peers are AGC Biologics and Miltenyi Biotec.

Does BioCentriq have an API?

No public API is recorded for BioCentriq.

What industry is BioCentriq in?

BioCentriq's product category is Cell Therapy Contract Development & Manufacturing. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 3254 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Roi-njBioCentriq partners with Orchestra Life Sciences to advance Princeton cell therapy facility developmentBioCentriq announced a partnership with Orchestra Life Sciences to support its Princeton cell therapy facility expansion. The collaboration backs a $12M CAPEX investment for facility optimization and digital integration, with Orchestra providing technical expertise. The partnership aims to complete the 60,000 sq. ft. facility by Q2 2025.PR NewswireBioCentriq Partners with Orchestra Life Sciences to Advance Princeton, NJ Cell Therapy Facility DevelopmentBioCentriq announced a partnership with Orchestra Life Sciences to support its $12M CAPEX investment in a new 60,000 sq. ft. Princeton, NJ cell therapy facility. The collaboration focuses on facility design, digital infrastructure, and GMP manufacturing capabilities, with completion targeted for Q2 2025.Roi-njBioCentriq expands operations and secures cell therapy manufacturing facility in PrincetonBioCentriq leased a cell therapy manufacturing facility in Princeton, adding a $12 million investment in upgrades and equipment. The 60,000 sq. ft. site includes six ISO 7 cleanrooms and 30,000 sq. ft. of expansion space. The facility is expected to be operational by Q2 2025.PR NewswireBioCentriq Expands Operations and Secures Cell Therapy Manufacturing Facility in Princeton, NJBioCentriq leased a Princeton, NJ cell therapy manufacturing facility as its new headquarters, investing $12M in upgrades. The 60,000 sq ft site includes six ISO 7 cleanrooms and expansion space, with operations expected by Q2 2025.Business & FinancialBiocentriq Appoints Syed T. Husain As Chief Executive OfficerBioCentriq appointed Syed T. Husain as CEO and Board member on Sept. 19, 2024. He brings over 20 years of CDMO leadership, including roles at Resilience, Emergent BioSolutions, and Lonza. The company aims to support cell therapy customers through clinical to commercial manufacturing.Premier-ResearchNavigating Cell Therapy Development: The benefits of working with a Clinical CRO – CDMO PartnershipA promotional article from Premier Research argues that cell therapy biotechs benefit from partnering with a clinical CRO that also has a cell therapy CDMO, citing regulatory, CMC, nonclinical, clinical, supply chain and quality assurance expertise. It states Premier Research partners with BioCentriq, a global cell therapy CDMO, since 2022. No financial figures or client names were disclosed.PR NewswireAutolomous and BioCentriq Partner to Speed Up Cell Therapy DeliveryAutolomous, a London-based developer of manufacturing management systems for cell and gene therapies, and BioCentriq, a clinical-phase cell therapy contract development and manufacturing organization (CDMO) based in New Jersey, announced a partnership on April 24, 2024 to digitize and accelerate process development and manufacturing activities. BioCentriq will implement Autolomous's autoloMATE platform, a no-code, cloud-native software solution, to replace paper-based systems and streamline operations, with the stated goal of accelerating batch delivery and improving patient access to cell therapies. The companies cited enhanced operational efficiency, reduced timelines, and data integrity as key benefits of the collaboration, with BioCentriq noting it will de-risk development schedules while maintaining quality standards.YahooAutolomous and BioCentriq Partner to Speed Up Cell Therapy DeliveryAutolomous and BioCentriq announced a partnership to digitize and accelerate cell therapy development and manufacturing using Autolomous' autoloMATE platform. The collaboration aims to streamline operations, enhance efficiency, and speed patient access to cell therapies. BioCentriq will use the platform to replace paper-based systems and de-risk timelines.ContractpharmaAutolomous and BioCentriq Partner to Transform OperationsAutolomous and BioCentriq partnered to digitize process development and manufacturing for cell therapies. BioCentriq will use Autolomous' autoloMATE platform to replace paper-based systems, aiming to accelerate batch delivery and improve operational efficiency. The partnership seeks to speed patient access to cell therapies.PR NewswireGC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.GC Cell and BioCentriq signed a process transfer agreement to bring Immuncell-LC, an autologous CIK cell therapy, to the U.S. market. The therapy reduced HCC recurrence by 37% and mortality by 79% in a Phase 3 trial, and has been administered to over 10,000 patients in South Korea.